Comprehensive analysis of autophagy-related prognostic genes in breast cancer

Jianguo Lai | Bo Chen | Hsiaopei Mok | Guochun Zhang | Chongyang Ren | Ning Liao

Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Correspondence
Ning Liao, Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, No. 106 Zhongshan Er Road, Guangzhou 510080, China. Email: syliaoning@scut.edu.cn

Funding information
Medical Scientific Research Foundation of Guangdong Province, Grant/Award Number: B2019039; National Natural Science Foundation of Guangdong Province, Grant/Award Number: 2016A030313768 and 2018A030313292; National Natural Science Foundation of China, Grant/Award Number: 81902828, 81602645, 81071851 and 81001189; Research Funds from Guangzhou Municipal Science and Technology Project, Grant/Award Number: 201707010418 and 201804010430

Abstract
Accumulating evidence revealed that autophagy played vital roles in breast cancer (BC) progression. Thus, the aim of this study was to investigate the prognostic value of autophagy-related genes (ARGs) and develop a ARG-based model to evaluate 5-year overall survival (OS) in BC patients. We acquired ARG expression profiling in a large BC cohort (N = 1007) from The Cancer Genome Atlas (TCGA) database. The correlation between ARGs and OS was confirmed by the LASSO and Cox regression analyses. A predictive model was established based on independent prognostic variables. Thus, time-dependent receiver operating curve (ROC), calibration plot, decision curve and subgroup analysis were conducted to determine the predictive performance of ARG-based model. Four ARGs (ATG4A, IFNG, NRG1 and SERPINA1) were identified using the LASSO and multivariate Cox regression analyses. A ARG-based model was constructed based on the four ARGs, two clinicopathological risk factors (age and TNM stage), dividing patients into high-risk and low-risk groups. The 5-year OS of patients in the low-risk group was higher than that in the high-risk group (P < 0.0001). Time-dependent ROC at 5 years indicated that the four ARG-based tool had better prognostic accuracy than TNM stage in the training cohort (AUC: 0.731 vs 0.640, P < 0.01) and validation cohort (AUC: 0.804 vs 0.671, P < 0.01). The mutation frequencies of the four ARGs (ATG4A, IFNG, NRG1 and SERPINA1) were 0.9%, 2.8%, 8% and 1.3%, respectively. We built and verified a novel four ARG-based nomogram, a credible approach to predict 5-year OS in BC, which can assist oncologists in determining effective therapeutic strategies.

KEYWORDS
autophagy, breast cancer, gene, model, prognosis
1 | INTRODUCTION

Breast cancer (BC) is the major health burden because of the high rates of morbidity and cancer death among women. Although great medical advances in BC screening, diagnosis, and comprehensive therapy, its survival outcome is not entirely satisfactory. Thus, individual treatment strategies of breast cancer still present huge challenges. Currently, therapeutic schemes and prognostic assessment for BC patients are mainly based on the tumour-node-metastasis (TNM) staging system and molecular subtypes. The TNM staging system has been widely applied for cancer management, but it is unable to achieve individualized survival prediction. In addition, some cases at the same TNM stage have distinct survival outcome. Then, many BC patients did not receive optimal treatment strategies and had to face with unfavourable survival prognosis. Therefore, the identification of novel signatures to improve prognostic assessment and clinically guide treatment decisions is indispensable in routine practice.

During the past decade, genome expression profiling can effectively provide detailed information for survival prediction in cancer patients. Moreover, gene biomarkers have been considered as an important tool to predict the prognostic outcome and treatment responses for cancer patients. Autophagy, also recognizing as type II programmed cell death, is a vital biological process that keeps the stability of the intracellular environment. Besides, autophagy can degrade and recycle components of aged or damaged organelles to promote rapid growth of cancer cells. Thus, autophagy-related proteins are able to regulate tumour growth and progression. Several studies have investigated the prognostic roles of autophagy-related gene (ARG) signatures in various tumours. However, little attention has been paid to identify the association between ARGs and overall survival (OS) in BC via high-throughput expression profiles. The high-throughput platform made contributions to genomic analysis in medical oncology with huge clinical significances. Thus, identifying a novel ARG signature using high-throughput expression profile to predict 5-year OS for BC patients is urgently needed.

Hence, in this study, to improve prognostic evaluation in BC patients, we sought to identify ARG signature from The Cancer Genome Atlas (TCGA) database. A nomogram integrating the prognostic ARGs and clinicopathological risk factors was established to predict 5-year OS and achieve effective risk stratification for BC patients.

2 | MATERIALS AND METHODS

2.1 | Patients and study design

The gene expression profiles and clinical information for BC patients were obtained from the TCGA database. Inclusion criteria were included: (a) patients with invasive BC; (b) complete gene expression profiles and follow-up information; and (c) survival time more than 1 month. Eventually, 1007 BC patients (training cohort) satisfying the inclusion criteria were selected in this study. Based on the computer allocation numbers, 504 cases as validation set were randomly confirmed from the training set.

We acquired TCGA data from public database (https://cancer.gov.nih.gov/), and hence, ethical approval and patient’s informed consent were waived in this study.

2.2 | Development of risk score and the ARG-based model

The 232 ARGs were acquired from the HADb (Human Autophagy Database, http://autophagy.lu/clustering/index.html). Firstly, univariate Cox proportional hazards regression analysis (CPHRA) was conducted to investigate the association between the expression level of ARGs and 5-year OS. Next, the ARGs were recognized as significant variables when the P value was <0.05 in the univariate CPHRA. Subsequently, the least absolute shrinkage and selection operator (LASSO) regression analysis was performed to screen out ARGs as candidate genes. LASSO regression analysis is able to shrink regression coefficients towards zero. And on the basis of the regulation weight λ, ARGs with the regression coefficients (equal to zero) were excluded. Finally, the multivariate CPHRA was implemented to identify the independent prognostic ARGs for 5-year OS in BC patients (P < 0.05). In the light of the expression values of selected ARGs, the risk score was constructed and weighted by multivariate Cox regression coefficients. The risk score = sum of regression coefficients × expression level of ARGs. Finally, a ARG-based model, integrating the prognostic ARGs and clinicopathological risk factors, was formulated. According to the ARG-based model, the prognostic nomogram score was calculated for each patient.

2.3 | Evaluation of the ARG-based model

The model accuracy of the ARG-based tool was estimated using time-dependent receiver operating characteristic (ROC) curve and the area under the curve (AUC) value. The calibration ability of the ARG-based model was assessed via the calibration plot. Calibration curve was executed to validate the agreement between nomogram-predicted and actual outcome. The risk stratification ability of the ARG-based model was validated by subgroup analysis. Decision curve analysis (DCA) has been advocated to assess the potential clinical utility of predictive nomogram. Herein, DCA was applied to evaluate the clinical usefulness of the model by quantifying the net benefits for a range of threshold probabilities. DCA was executed as an analytical method that combined the results of a decision to quantify the clinical practicability of a model. Thus, the DCA can weigh the net benefit to assess the clinical utility of a nomogram.
2.4 | Statistical analysis

Distribution differences in variables in the two independent cohorts were evaluated using the chi-square and the Mann–Whitney U test. Univariate, LASSO and multivariate Cox regression analyses were performed to identify the independent indicators of OS ($P < 0.05$). Then, Cox regression coefficients were used to build a risk score and four ARG-based nomogram. Time-dependent ROC curve analysis is extensively carried out to assess the predictive performance of the four ARG-based model. Survival curves were drawn using the Kaplan-Meier method and contrasted via the log-rank test. OS (primary end-point) was calculated as the interval from surgery to the time of death or last follow-up. We confirmed the optimal cut-off value of the ARG-based nomogram using X-tile plot. Statistical analyses were applied via Stata/MP, version 14.0 (StataCorp LP, College Station, TX, USA) and R version (3.4.4, www.r-project.org). $P < 0.05$ was considered as statistically significant.

3 | RESULTS

3.1 | Identification of the four ARG signatures

The detailed flow chart of the study procedure is presented in Figure 1. And detailed baseline characteristics of included patients are shown in Table 1. There were no distinct differences in patient characteristics between two independent cohorts in Table 1 ($P > 0.05$). In the light of univariate CPHRA, 39 ARGs were preliminary screen out in the training cohort ($P < 0.05$). Subsequently, LASSO Cox regression analysis was carried out to determine 17 ARGs as candidate genes in the primary data set (Figure S1). To assess the potential function of the 17 prognostic ARGs, functional enrichment analysis was performed via Metascape database (http://metascape.org/). And the result suggested that the 17 ARGs mainly enriched in autophagy, positive regulation of protein localization to membrane, pid delta np63 pathway, glial cell.
differentiation, regulation of cellular response to heat and establishment of protein localization to organelle (Figure S2). Next, multivariate CPHRA was applied to further identify four ARGs (ATG4A, IFNG, NRG1 and SERPINA1) as independent prognostic indicators in the training cohort. Moreover, we also found that the mutation frequencies of the four ARGs (ATG4A, IFNG, NRG1 and SERPINA1) were 0.9%, 2.8%, 8% and 1.3% in the TCGA database, respectively. The common mutation type of the four ARGs was copy-number amplification (Figure S3). Some studies have revealed that abnormal DNA methylation is a vital mechanism for epigenetic silencing of gene expression in variety of tumours. Thus, we explored this relationship between the four ARGs and DNA methylation in the TCGA database via the MEXPRESS tool (http://mexpress.be/).  

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | HR (95% CI)         | P value | HR (95% CI) | P value |
| Age       | 1.033 (1.019-1.047) | <0.001  | 1.028 (1.014-1.043) | <0.001 |
| T stage   |                     |         |             |         |
| T1        | Referent            |         |             |         |
| T2        | 1.188 (0.785-1.799) | 0.415   |             |         |
| T3        | 1.299 (0.744-2.268) | 0.357   |             |         |
| T4        | 3.414 (1.779-6.551) | <0.001  |             |         |
| Tx        | 0.571 (0.077-4.240) | 0.584   |             |         |
| N stage   |                     |         |             |         |
| N0        | Referent            |         |             |         |
| N1        | 1.819 (1.212-2.731) | 0.004   |             |         |
| N2        | 2.795 (1.633-4.783) | <0.001  |             |         |
| N3        | 4.136 (2.199-7.780) | <0.001  |             |         |
| Nx        | 6.506 (3.150-13.437)| <0.001  |             |         |
| TNM stage |                     |         |             |         |
| I         | Referent            |         | Referent    |         |
| II        | 1.456 (0.838-2.528) | 0.183   | 1.463 (0.840-2.550) | 0.179 |
| III       | 2.651 (1.473-4.772) | <0.001  | 2.6737 (1.477-4.841) | 0.001 |
| IV        | 11.143 (5.422-22.901)| <0.001  | 7.3441 (3.555-15.168) | <0.001 |
| Unknown   | 2.975 (1.333-6.643) | 0.008   | 2.9272 (1.306-6.561) | 0.009 |
| Risk score| 2.718 (2.050-3.604) | <0.001  | 2.373 (1.774-3.175) | <0.001 |

Note: Bold values indicate statistical significance (P < 0.05).
Abbreviations: CI, confidence interval, HR, hazard ratios.
expression in the promoter region located close to the TSS and gene body \( (P < 0.05) \). However, IFNG expression was positively correlated with DNA methylation in its 3′UTR with (Pearson \( r = +0.336, P < 0.001 \)). These results suggested that the multiple DNA methylation regions may play important roles in regulating the four ARG expression.

### 3.2 Establishment of four ARG–based risk score and prognostic model

Using the multivariate Cox regression coefficients, we computed a risk score for each patient: risk score = \((0.903 \times \text{expression level of} \) }\)

---

**FIGURE 3** A, Time-dependent receiver operating characteristic (ROC) curves at 5 y based on the four ARG–based prognostic model in the training cohort and validation cohort. B, Calibration curves of the four ARG–based prognostic model in the training cohort and validation cohort. Decision curve of the four ARG–based prognostic model in the training cohort (C) and validation cohort (D). Comparisons of the predictive accuracy at 5-y OS using time-dependent ROC curves in the training cohort (E) and validation cohort (F)
ATG4A) + (−0.566 × expression level of IFNG) + (−0.667 × expression level of NRG1) + (−0.214 × expression level of SERPINA1). The univariate and multivariate CPHRs in the training set are presented in Table 2. Finally, the risk score and two clinicopathological risk factors (age and TNM stage) were verified as independent predictors for 5-year OS \( (P < 0.05) \). Thus, to provide the oncologists with a quantitative technique for predicting the 5-year OS, we developed an ARG-based nomogram, which incorporated the four ARG-based risk score and two clinicopathological risk factors (age and TNM stage) (Figure 2).

### 3.3 Assessment of the four ARG-based prognostic model

The AUC of the four ARG-based model was 0.731 (95% CI: 0.662-0.801) and 0.804 (95% CI: 0.715-0.893) in the training and validation groups, indicating that this nomogram had a high predictive accuracy (Figure 3A). Calibration curves indicated great agreement between four ARG-based model-predicted probabilities and the actual observations of 5-year OS, showing that this model had good calibration ability (Figure 3B). The DCA demonstrated that the four ARG-based model added more net benefit than the risk score and TNM stage in the training and validation cohorts, suggesting that our model had higher clinical utility (Figure 3C-D). Besides, to investigate whether the four ARG signatures added additional prognostic value of 5-year OS, time-dependent ROC curve was conducted to compare the predictive performances between the ARG-based nomogram, clinicopathological risk factors and risk score in the training and validation data sets, revealing that prognostic accuracy of the four ARG-based model was superior to risk score and clinical risk factors (Figure 3E-F). Each patient can be allocated a prognostic score on the basis of the four ARG-based nomogram. Using X-tile plot, the optimal cut-off value of the four ARG-based prognostic score was 1.53. Hence, patients were classified into the high-risk group \( (N = 252) \) and low-risk group \( (N = 755) \) in the training cohort. To identify the robustness of the four ARG-based model, it was further tested in the validation data set via the same cut-off point. Then, BC patients were classified into the low-risk group \( (N = 384) \) and the high-risk group \( (N = 120) \) in the validation cohort. The distribution characteristics of prognostic

**FIGURE 4** The distribution of model score, OS and OS status in the training cohort (A) and validation cohort (B). The dotted line reveals the optimal cut-off point of the model score to classify patients into the low- and high-risk group. Kaplan-Meier curves of the low- and high-risk patients based on the four ARG-based prognostic model in the training cohort (C) and validation cohort (D).
scores and survival status are manifested in Figure 4, which demonstrated that patients with higher scores had worse OS than that of those with lower scores \( (P < 0.001) \). Stratified analyses were applied for BC patients in T stage, N stage and TNM stage, suggesting that the four ARG-based model had distinct risk stratification ability (Figure 5). The patients with high-risk scores had distinctly worse OS than patients with low-risk scores in T1 \( (P = 0.00022) \), T2 \( (P < 0.0001) \), T3/4 \( (P < 0.0001) \), N0 \( (P < 0.0001) \), N1 \( (P < 0.0001) \), N2 \( (P = 0.00011) \) and N3 \( (P = 0.015) \), TNM stage I/II \( (P < 0.0001) \) and TNM stage III/ IV \( (P < 0.0001) \) (Figure 5).

4 | DISCUSSION

In the genomic era, novel crucial strategies are imperative to predict survival prognosis and further guide individual treatment for BC patients. Nevertheless, BC progression and survival outcome can vary noticeably owing to the discrepant genes, even though some BC patients are in the identical TNM stage, suggesting the conventional staging technique could not be sufficient for accurate prediction in BC prognosis. In the current circumstances, it is urgent to establish a novel model to accurately predict patients’ survival prognosis. Never before has a study proposed an accurate model taken into account ARGs and clinical features to evaluate the 5-year OS in BC patients. Accordingly, in consideration of the inherent deficiency of TNM stage system, a novel prognostic model on the basis of the four ARGs (ATG4A, IFNG, NRG1 and SERPINA1) and two clinicopathological factors (age and TNM stage) was constructed to improve individual prediction of 5-year OS and achieve effective subgroup stratification for BC patients. In terms of predictive accuracy, the AUC of the four ARG-based model distinctly outperformed the current TNM stage system. Moreover, the calibration curves revealed outstanding agreement between the actual and model-predicted survival probabilities, ensuring the calibration ability of our model. Furthermore, the DCA demonstrated that the four ARG-based nomogram had favourable clinical application across the wider range of threshold probability. In addition, the four ARG-based classifier noticeably stratified BC patients into two risk groups. To our knowledge, this is the first study to perform comprehensive analysis of autophagy-related prognostic genes in BC. Hence, the novel

![Figure 5](image-url) Subgroup analysis of the four ARG-based prognostic model for breast cancer patients in T stage, N stage and TNM stage
ARG-based signature could help identify the high-risk patients and guide individualized treatment of BC patients, which is credible to be applied in clinical application.

In the past decade, accumulating advanced technologies have been exploited to perform transcriptome analysis, including high-throughput sequence and microarray methods. Recently, many multi-gene-based biomarkers had been established to predict survival outcome in BC patients. However, on one hand, some previous studies did not apply LASSO Cox regression model to identify the gene signatures. As we known, LASSO has been considerably applied to select optimal variables with a high prognostic ability and avoid overfitting in high-dimensional data. Therefore, the previous multi-gene-based models may be not reliable and robust in those studies. On the other hand, growing evidence indicated that autophagy played vital roles in multiple tumour progression, which facilitated us to exploit its importance as prognostic biomarker. Although several researches had investigated the pivotal roles of ARGs in patients’ prognosis, the ARG biomarker in BC is still unknown. The ATG4A (autophagy-related 4A cysteine peptidase) is involved in regulating autophagy. Wolf et al reported that ATG4A was imperative for cancer stem cell maintenance and to regulate BC cell tumorigenicity. And our study elucidated that high expression of ATG4A in BC was associated with poor OS. In concordance with our finding, Yeong et al manifested that high expression of IFNG (interferon gamma) was correlated with favourable survival outcome. Chan et al demonstrated that high expression of SERPINA1 (serpin family A member 1) may be a predictive indicator for better BC prognosis, which was in accordance with our study. The role of NRG1 (neuregulin 1) in BC prognosis should be verified. Inevitably, several limitations should be presented in this study. First of all, the established ARG-based model was stem from the TCGA database. Thus, this nomogram needed to be tested in larger clinical trials with adequate information (adjuvant therapy strategies) in the future. Besides, several crucial clinical risk factors, such as hormone receptor, molecular subtype, adjuvant chemotherapy, ki67 and radiotherapy, were unavailable in the TCGA database. Herein, we are unable to conduct stratification analyses in these subgroup patients. And more biomarkers should be integrated into our model to improve predictive accuracy in the future. Last but not least, some functional experiments on the role of the four ARGs in BC are still needed to be exploited in the future studies.

In conclusion, to provide an accurate quantitative method that could assess the likelihood of 5-year OS in BC, an effective predictive model was formulated by incorporating the four ARGs and two clinico-pathological risk factors (age and TNM stage). Thus, this nomogram has the potential to identify the high-risk patients and guide individualized efficient therapeutic strategies for BC patients.

ACKNOWLEDGEMENTS

This research was supported by the National Natural Science Foundation of China (grants 81902828, 81602645, 81071851 and 81001189), National Natural Science Foundation of Guangdong Province (grants 2016A030313768 and 2018A030313292), Medical Scientific Research Foundation of Guangdong Province (B2019039, Bo Chen) and Research Funds from Guangzhou Municipal Science and Technology Project (201707010418 and 201804010430), the Doctor Launch Fund of Guangdong Provincial People’s hospital (grant number 2020bq11).

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTION

Jianguo Lai: Conceptualization (lead); Project administration (lead); Writing-original draft (lead); Writing-review & editing (lead). Bo Chen: Conceptualization (lead); Funding acquisition (lead); Project administration (lead); Writing-original draft (lead); Writing-review & editing (lead). Hsiaopei Mok: Data curation (lead); Resources (lead); Software (lead). Guochun Zhang: Formal analysis (lead); Investigation (lead); Supervision (lead). Chongyang Ren: Data curation (equal); Investigation (lead); Resources (lead); Software (equal); Visualization (lead). Ning Liao: Conceptualization (lead); Funding acquisition (lead); Project administration (lead); Writing-original draft (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT

The data sets used and analysed during the current study are available from the corresponding author on reasonable request.

ORCID

Jianguo Lai https://orcid.org/0000-0002-0120-0245
Ning Liao https://orcid.org/0000-0002-1780-5652

REFERENCES

1. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
3. Lai J, Chen BO, Zhang G, et al. Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer. Aging. 2019;11(18):7525-7536.
4. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(27):2804-2807.
5. Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(26):2736-2740.
6. Lai J, Wang H, Pan Z, Su F. A novel six-microRNA-based model to improve prognosis prediction of breast cancer. Aging. 2019;11(2):649-662.
7. Henriksen SD, Madsen PH, Larsen AC, et al. Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker
for pancreatic adenocarcinoma staging. *Int J Cancer.* 2017;141(12): 2489-2497.
8. Wu S, Chen J-N, Zhang Q-W, et al. A new metastatic lymph node classification-based survival predicting model in patients with small bowel adenocarcinoma: a derivation and validation study. *EBioMedicine.* 2018;32:134-141.
9. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. *Lancet Oncol.* 2015;16(4):e173-e180.
10. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017;67(4):290-303.
11. Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers. *Clin Cancer Res.* 2018;24(19):4887-4899.
12. Kan Z, Ding Y, Kim J, et al. Multi-omics profiling of younger Asian breast cancers reveals distinct molecular signatures. *Nat Commun.* 2018;9(1):1725.
13. Kim SY, Kawaguchi T, Yan L, Young J, Qi Q, Takabe K. Clinical relevance of microRNA expressions in breast cancer validated using the cancer genome atlas (TCGA). *Ann Surg Oncol.* 2017;24(10):2943-2949.
14. Liu J, Nie S, Gao M, et al. Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis. *J Cell Physiol.* 2019;234(11):21260-21273.
15. Liu GM, Xie WX, Zhang CY, Xu JW. Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma. *J Cell Physiol.* 2020;235(2):1624-1636.
16. Chen Q, Yu D, Zhao Y, Qiu J, Xie Y, Tao M. Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis. *J Cell Biochem.* 2019;120(12):19496-19508.
17. Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer development and therapy. *Cancer Res.* 2010;70(9):3431-3434.
18. Macintosh RL, Ryan KM. Autophagy in tumour cell death. *Semin Cancer Biol.* 2013;23(5):344-351.
19. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. *Nat Rev Clin Oncol.* 2011;8(9):528-539.
20. Yun CW, Lee SH. The roles of autophagy in cancer. *Int J Mol Sci.* 2018;19(11):3466.
21. Zhou Z, Mo S, Dai W, et al. Development and validation of an autophagy score signature for the prediction of post-operative survival in colorectal cancer. *Front Oncol.* 2019;9:878.
22. Wang SS, Chen G, Li SH, et al. Identification and validation of an individualized autophagy-clinical prognostic index in bladder cancer patients. *OncoTargets Ther.* 2019;12:3695-3712.
23. Van B, Liu B, Yu G, Huang Y, Lv C. Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma. *Aging.* 2019;11(20):9025-9042.
24. Mo S, Dai W, Xiang W, et al. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. *Carcinogenesis.* 2019;40(7):861-870.
25. Luan F, Chen W, Chen M, et al. An autophagy-related long non-coding RNA signature for glioma. *FEBS Open Bio.* 2019;9(4):653-667.
26. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. *BMJ.* 2016;352:i6.
27. Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet.* 2016;387(10035):2302-2311.
28. Han SS, Rivera GA, Tammemägi MC, et al. Risk stratification for second primary lung cancer. *J Clin Oncol.* 2017;35(25):2893-2899.
29. Fitzgerald M, Saville BR, Lewis RJ. Decision curve analysis. *JAMA.* 2015;313(4):409-410.
30. Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. *J Clin Oncol.* 2016;34(21):2534-2540.
31. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ.* 2015;350:g7594.
32. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res.* 2004;10(21):7252-7259.
33. Qiu J, Peng B, Tang Y, et al. CpG methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. *J Clin Oncol.* 2017;35(7):734-742.
34. Su S, Chen J, Yao H, et al. CD10(+)/GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. *Cell.* 2018;172(4):841-856.
35. Koch A, De Meyer T, Jeschke J, Van Criekinge W. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. *BMC Genom.* 2015;16:636.
36. Yu C, Qin NA, Pu Z, et al. Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer. *Breast Cancer Res Treat.* 2019;175(3):691-699.
37. Xie X, Wang J, Shi D, et al. Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. *J Cell Mol Med.* 2019;23(2):1439-1447.
38. Tang J, Cui Q, Zhang D, Liao X, Zhu J, Wu G. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment. *J Cell Mol Med.* 2019;23(8):4980-4990.
39. Lv X, He M, Zhao Y, et al. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer. *Cancer Cell Int.* 2019;19(1):172.
40. Liu M, Zhou S, Wang J, et al. Identification of genes associated with survival of breast cancer patients. *Breast Cancer.* 2019;26(3):317-325.
41. Chen B, Tang H, Chen X, et al. Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. *Cancer Manage Res.* 2019;11:179-190.
42. Haibe-Kains B, Desmedt C, Loi S, et al. A three-gene model to robustly identify breast cancer molecular subtypes. *J Natl Cancer Inst.* 2012;104(4):311-325.
43. Wolf J, Dewi DL, Fredebohm J, et al. A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. *Breast Cancer Res.* 2013;15(6):R109.
44. Yeong J, Lim JCT, Lee B, et al. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. *J Immunother Cancer.* 2019;7(1):34.
45. Chan HJ, Li H, Liu Z, Yuan YC, Mortimer J, Chen S. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients. *Oncotarget.* 2015;6(28):25815-25827.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Lai J, Chen B, Mok H, Zhang G, Ren C, Liao N. Comprehensive analysis of autophagy-related prognostic genes in breast cancer. *J Cell Mol Med.* 2020;24:9145-9153. [https://doi.org/10.1111/jcmm.15551](https://doi.org/10.1111/jcmm.15551)